Answers are grounded in this paper and cite their sources.
Observational study shows low thrombotic complications and high survival on left ventricular assist device support, indicating good clinical outcomes.
Long-term survival on HeartMate 3 LVAD support exceeded 60% at 5 years in this single-center cohort. While adverse events such as device related infections and heart failure hospitalizations continue to pose a substantial clinical challenge, the incidence of thrombotic complications was low, underscoring improvement in clinical outcomes with current generation centrifugal LVAD devices.
No takes yet. Share an insight, caveat, or question.
Legtenberg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: